X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cipla with Divis Laboratories - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs DIVIS LABORATORIES - Comparison Results

CIPLA    Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA DIVIS LABORATORIES CIPLA/
DIVIS LABORATORIES
 
P/E (TTM) x 33.9 34.5 98.2% View Chart
P/BV x 3.0 6.7 44.0% View Chart
Dividend Yield % 0.6 0.7 85.8%  

Financials

 CIPLA   DIVIS LABORATORIES
EQUITY SHARE DATA
    CIPLA
Mar-18
DIVIS LABORATORIES
Mar-18
CIPLA/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs6631,142 58.1%   
Low Rs479533 89.9%   
Sales per share (Unadj.) Rs189.0146.6 129.0%  
Earnings per share (Unadj.) Rs17.633.0 53.3%  
Cash flow per share (Unadj.) Rs34.038.4 88.6%  
Dividends per share (Unadj.) Rs3.0010.00 30.0%  
Dividend yield (eoy) %0.51.2 44.0%  
Book value per share (Unadj.) Rs176.7222.8 79.3%  
Shares outstanding (eoy) m805.12265.47 303.3%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x3.05.7 52.9%   
Avg P/E ratio x32.525.3 128.0%  
P/CF ratio (eoy) x16.821.8 77.0%  
Price / Book Value ratio x3.23.8 86.0%  
Dividend payout %17.130.3 56.3%   
Avg Mkt Cap Rs m459,724222,318 206.8%   
No. of employees `00023.610.8 219.4%   
Total wages/salary Rs m26,9014,561 589.9%   
Avg. sales/employee Rs Th6,446.13,616.0 178.3%   
Avg. wages/employee Rs Th1,139.4423.8 268.9%   
Avg. net profit/employee Rs Th600.0814.9 73.6%   
INCOME DATA
Net Sales Rs m152,19338,915 391.1%  
Other income Rs m3,5771,134 315.3%   
Total revenues Rs m155,76940,049 388.9%   
Gross profit Rs m28,26412,617 224.0%  
Depreciation Rs m13,2281,425 928.4%   
Interest Rs m1,14213 8,588.7%   
Profit before tax Rs m17,47012,313 141.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m-280-   
Extraordinary Inc (Exp) Rs m-7750-   
Tax Rs m2,5013,543 70.6%   
Profit after tax Rs m14,1668,770 161.5%  
Gross profit margin %18.632.4 57.3%  
Effective tax rate %14.328.8 49.8%   
Net profit margin %9.322.5 41.3%  
BALANCE SHEET DATA
Current assets Rs m108,14145,351 238.5%   
Current liabilities Rs m38,3226,507 588.9%   
Net working cap to sales %45.999.8 46.0%  
Current ratio x2.87.0 40.5%  
Inventory Days Days97127 76.6%  
Debtors Days Days7495 78.2%  
Net fixed assets Rs m109,41121,160 517.1%   
Share capital Rs m1,610531 303.3%   
"Free" reserves Rs m140,68258,625 240.0%   
Net worth Rs m142,29259,156 240.5%   
Long term debt Rs m36,6210-   
Total assets Rs m228,60667,832 337.0%  
Interest coverage x16.3926.8 1.8%   
Debt to equity ratio x0.30-  
Sales to assets ratio x0.70.6 116.0%   
Return on assets %6.712.9 51.7%  
Return on equity %10.014.8 67.2%  
Return on capital %10.020.8 47.8%  
Exports to sales %32.80-   
Imports to sales %021.8 0.0%   
Exports (fob) Rs m49,883NA-   
Imports (cif) Rs mNA8,485 0.0%   
Fx inflow Rs m51,69132,359 159.7%   
Fx outflow Rs m21,0339,042 232.6%   
Net fx Rs m30,65823,317 131.5%   
CASH FLOW
From Operations Rs m14,6287,759 188.5%  
From Investments Rs m-8,540-4,783 178.6%  
From Financial Activity Rs m-3,855-3,142 122.7%  
Net Cashflow Rs m2,431-166 -1,464.5%  

Share Holding

Indian Promoters % 16.0 52.0 30.8%  
Foreign collaborators % 20.8 0.0 -  
Indian inst/Mut Fund % 12.2 11.8 103.4%  
FIIs % 23.7 19.0 124.7%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 17.2 152.3%  
Shareholders   161,166 31,796 506.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   JUBILANT LIFE SCIENCES  DR. DATSONS LABS  WOCKHARDT LTD.  GSK PHARMA  PANACEA BIOTECH  

Compare CIPLA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Marginally Higher; Telecom and Oil & Gas Stocks Witness Buying(Closing)

Indian share markets continued to trade near the dotted line during closing hours and ended the day marginally higher. Gains were largely seen in the telecom sector.

Related Views on News

CIPLA Announces Quarterly Results (2QFY19); Net Profit Down 15.8% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, CIPLA has posted a net profit of Rs 4 bn (down 15.8% YoY). Sales on the other hand came in at Rs 40 bn (down 1.7% YoY). Read on for a complete analysis of CIPLA's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (2QFY19); Net Profit Up 92.3% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 92.3% YoY). Sales on the other hand came in at Rs 13 bn (up 44.3% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

It's Almost the Perfect Time to Buy This Safe Stock(The 5 Minute Wrapup)

Dec 6, 2018

My latest StockSelect recommendation ticks all the boxes of a great safe stock.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

Are Foreign Investors Heading Back to the Indian Stock Markets?(Chart Of The Day)

Dec 3, 2018

After months of heavy FII selling, November witnessed a return on foreign money into Indian equities...

DSP Mutual Fund's Sale of DHFL Bonds: Here's What You Need to Know(Outside View)

Dec 5, 2018

PersonalFN explains the probable reason as to why the capital market regulator has initiated DSP Mutual Fund's bond sale that caused DHFL stock to crash.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Dec 14, 2018 03:35 PM

TRACK CIPLA

COMPARE CIPLA WITH

MARKET STATS